Baricitinib X crystal form, preparation method thereof and pharmaceutical composition containing baricitinib X crystal form

By developing the X crystal form of baritinib, its preparation method and direct powder tableting process, the problems of stability and fluidity of different crystal forms of baritinib were solved, and simplified process and efficient preparation of pharmaceutical compositions were achieved. , suitable for industrial production and ensures the therapeutic effect and production efficiency of drugs.

CN118955511APending Publication Date: 2024-11-15CENT TESTING INT GRP CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411449451.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The different crystal forms of existing baritinib have differences in stability, fluidity and compressibility in drug production and use, which affect the therapeutic effect of the drug and industrial production efficiency. The existing preparation methods are complex and are not suitable for industrial production.

Method used

A new type of baritinib X crystal form and its preparation method were developed. Baritinib X crystal form was obtained by heating and stirring in an organic solvent system, adding purified water to crystallize, cooling and drying, and direct powder tableting process was adopted. Prepare pharmaceutical compositions, simplify processes and are suitable for continuous industrial production.

Benefits of technology

The baritinib X crystal form has excellent powdery properties, good particle size uniformity, good fluidity and compressibility, suitable for direct powder pressing process, and is stable under strong light, high temperature and high humidity conditions, avoiding The problem of debris or lobes of the tablets, and the in vitro release degree of the pharmaceutical composition is basically consistent with the marketed products, meeting application needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955511A_ABST
    Figure CN118955511A_ABST
Patent Text Reader

Abstract

The invention discloses a baricitinib X crystal form, a preparation method thereof and a pharmaceutical composition containing the compound, and the X-ray powder diffraction pattern of the baricitinib X crystal form has characteristic peaks when the 2theta value is 4.26 degrees + / -0.2 degrees, 12.58 degrees + / -0.2 degrees, 16.39 degrees + / -0.2 degrees, 16.77 degrees + / -0.2 degrees, 19.17 degrees + / -0.2 degrees, 19.34 degrees + / -0.2 degrees, 25.21 degrees + / -0.2 degrees, 25.44 degrees + / -0.2 degrees and 29.48 degrees + / -0.2 degrees. The baricitinib X crystal form disclosed by the invention has excellent powder chemical properties and stable physicochemical properties, is convenient in a medicine production process, can be subjected to industrial production and meets market requirements.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new solid form of baricitinib, and in particular to a baricitinib X crystal form and a preparation method thereof, and a pharmaceutical composition containing the compound. Background Art

[0002] The chemical name of Baricitinib is: 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, and its structural formula is as follows: , Baricitinib is a reversible, selective inhibitor of tyrosine protein kinase JAK1 / JAK2. It temporarily occupies the ATP binding site of JAK, regulates the JAK-STAT signal transduction pathway, blocks the phosphorylation and activation of signal transduction and transcription activators, and alleviates inflammation and other symptoms of the disease by blocking JAK. In February 2017, baricitinib was first approved for marketing in the European Union, and in June 2019 it was approved in China under the trade name of Alemin. ® / Olumiant ® , available in 2 mg and 4 mg strengths, for the treatment of rheumatoid arthritis and alopecia areata.

[0003] Different solid forms of active pharmaceutical ingredients usually have different physical and chemical properties, such as dissolution rate, solubility, chemical stability, physical stability, hygroscopicity, melting point, morphology, flowability, bulk density and compressibility. APIs of different crystalline forms have different physical and chemical properties, which will affect the production process and stability of drug preparations. Due to the differences in the internal crystal structure of drug polymorphs, different crystalline forms of the same solid drug will also show different physical and chemical properties, including powder properties, melting point, solubility, mechanical properties and physicochemical stability, etc. There is even a risk of mutual transformation between different crystalline forms under certain conditions, which directly affects the final quality of the product and the therapeutic effect of the drug.

[0004] Although the amorphous form of baricitinib has higher solubility and dissolution rate than the crystalline form in most cases, it is unstable, highly hygroscopic, and prone to crystalline transformation, so there are certain limitations in its use. Baricitinib also has a variety of crystalline forms, and different crystalline forms may have different bioavailability. In addition, their stability, fluidity, and compressibility may also be different. These physical and chemical properties have a certain impact on the application of the drug, thereby affecting the efficacy of the drug.

[0005] The prior art discloses a variety of different crystal forms and preparation methods of free forms of baricitinib, such as the original product Alamine that has been marketed. ® / Olumiant ®The baricitinib form I is used in the present invention. The XRPD spectrum of the form I has one or more characteristic peaks at positions of 2theta of 15.33, 16.66, 19.06, 14.91, 16.25, 15.74, 25.51, 12.40, and 17.39, wherein the error range of the 2theta value is ±0.20°. The preparation method thereof is as follows: adding the baricitinib compound to one or more solvent systems selected from the following: water, alcohols, ketones, esters, aromatic hydrocarbons, halogenated hydrocarbons, nitriles, nitroalkanes, cyclic ethers or aliphatic hydrocarbons, or a mixed system thereof, and preparing the baricitinib compound by adding an anti-solvent, suspending and stirring, heating and cooling crystallization, or volatile crystallization. The XRPD spectrum of baricitinib II crystal form has one or more characteristic peaks at positions of 2theta of 18.00, 10.80, 7.26, 14.60, 12.14, 11.21, 22.59, 22.03, and 19.64, wherein the error range of the 2theta value is ±0.20°. The preparation method of crystal form II is: adding the solid of the compound to glacial acetic acid or a mixed system of glacial acetic acid and other solvents, and preparing it by adding an anti-solvent, volatilizing, heating and cooling, or suspending and stirring. The other organic solvents include but are not limited to water, alcohols, ketones, esters, aromatic hydrocarbons, halogenated hydrocarbons, nitriles, nitroalkanes, cyclic ethers, and aliphatic hydrocarbon solvents. The XRPD patterns of baricitinib Form A are at 2theta=12.46, 13.92, 14.94, 15.36, 16.26, 16.64, 17.36, 19.08, 20.32, 21.96, 22.38, 24.12, 25.42, 27.44, 28.38, 29.32, 29.80, 32.68, 33.14, 33.56 , 33.92, and 41.60, wherein the 2theta value error range is ±0.2, and there are two preparation methods: (1) dissolving baricitinib in a first organic solvent (preferably: N,N-dimethylformamide) at a ratio of 1:1 to 1:5 g / mL, adding water or a second organic solvent (alcohol and / or ether) to the resulting solution to precipitate a solid, standing, then filtering, and vacuum drying to obtain. (2) adding a solvent to baricitinib at a ratio of 1:30 to 1:100 g / mL, ultrasonically treating, suspending at room temperature or a temperature higher than room temperature, then filtering, and vacuum drying to obtain a white powder of baricitinib A crystal form, wherein the solvent is any one of water, alcohols, ethers, esters, ketones, aliphatic hydrocarbons, aromatic hydrocarbons, or halogenated hydrocarbons, or a mixed solvent of two or more solvents in any proportion.The XRPD spectrum of baricitinib G crystalline form has 3, or 4, or 5, or 6, or 7, or 8, or 9 characteristic peaks at 2theta of 10.9, 14.4, 16.5, 18.2, 19.0, 21.8, 22.8, 23.8, and 26.9, wherein the error range of 2theta value is ±0.2°. The preparation method is: heat the baricitinib chloroform solvate from room temperature to 212°C, retain it for 10 minutes, and then take out the sample to obtain crystalline form G. The prior art also discloses the D form of baricitinib (the XRPD spectrum has characteristic peaks at 2theta of 9.4, 12.4, 16.6, 17.5, 19.0, 19.9, 21.3, 25.5, and 26.1, wherein the error range of the 2theta value is ±0.2°), the E form (the XRPD spectrum has characteristic peaks at 2theta of 9.7, 18.1, 19.1, 21.3, 21.5, 22.5, 24.6, 26.6, and 27.7, wherein the error range of the 2theta value is ±0.2° ), F crystal form (the XRPD spectrum has characteristic peaks at 2theta of 9.0, 15.5, 16.9, 17.3, 18.1, 20.0, 22.1, 23.6, and 26.3, and the error range of 2theta value is ±0.2°), G crystal form and even M1-M8 crystal forms. Compared with other published crystal forms, crystal form G has higher solubility, lower hygroscopicity, higher density, better fluidity and better adhesion. However, since the preparation of crystal form G requires heating to 212°C, the preparation conditions are relatively harsh and not convenient for industrial production.

[0006] In the pharmaceutical production process, whether it is a raw material or a pharmaceutical preparation containing an active compound, it is crucial for continuous industrial production to be able to use a convenient handling and processing form. The different physical properties of the crystalline form and the crystalline form relative to the amorphous form will significantly affect the chemical processing and pharmaceutical processing of the compound, especially when the compound is prepared or used on an industrial scale.

[0007] The preparation process of tablets mainly includes wet granulation tableting, dry granulation tableting and direct powder tableting. Wet granulation tableting is the main method of tablet production, but its process is relatively complicated. It is necessary to add adhesives to make soft materials and then dry and sieve the wet granules to obtain granules for tableting. It has great limitations for drugs that are unstable to moisture and heat, and will reduce the quality assurance of the product. Dry granulation can improve the physical properties of the raw powder and solve the problems of uneven powder particle size, uneven density, poor fluidity and easy stratification. The original product Alamine that has been launched on the market ® / Olumiant ® Due to the poor fluidity of the medium I crystal form, the dry granulation process is adopted in the industrialization process of the preparation. However, this process requires multiple steps such as premixing, dry granulation, total mixing, tableting and coating, which is not conducive to cost control.

[0008] Therefore, developing a new crystalline form of baricitinib with excellent powder properties, simple preparation process and the ability to be continuously industrially produced is an urgent research and development direction. Summary of the invention

[0009] In view of the defects in the prior art, the present invention proposes a baricitinib X crystal form and a preparation method thereof and a pharmaceutical composition comprising the compound. The baricitinib X crystal form of the present invention is not only easy to prepare, but also has excellent powder properties. The preparation method of the pharmaceutical composition comprising the crystal form of baricitinib has the advantages of simple process, no need for granulation, suitability for continuous industrial production and stable quality.

[0010] The present invention provides a baricitinib crystal form X, whose X-ray powder diffraction pattern has characteristic peaks at 2theta values ​​of 4.26°±0.2°, 12.58°±0.2°, 16.39°±0.2°, 16.77°±0.2°, 19.17°±0.2°, 19.34°±0.2°, 25.21°±0.2°, 25.44°±0.2°, and 29.48°±0.2°.

[0011] Furthermore, its X-ray powder diffraction pattern has characteristic peaks at one or more of the 2theta values ​​of 25.63°±0.2°, 29.93°±0.2°, 33.29°±0.2°, 37.24°±0.2°, and 38.14°±0.2°.

[0012] Furthermore, its X-ray powder diffraction pattern has characteristic peaks at 2theta values ​​of 25.63°±0.2°, 29.93°±0.2°, 33.29°±0.2°, 37.24°±0.2°, and 38.14°±0.2°.

[0013] Furthermore, its X-ray powder diffraction pattern is similar to Figure 1 Consistent.

[0014] Further, it has an endothermic peak at 215±2° C. in DSC analysis.

[0015] The present invention also provides a method for preparing the baricitinib X crystal form, comprising the following steps: Add baricitinib to an organic solvent system, heat up and stir, add a small amount of purified water and keep warm and stir to dissolve, continue to add a large amount of purified water to crystallize, keep warm and stir again, then cool down, age, filter and dry to obtain baricitinib Form X; The ratio of the mass of baricitinib to the volume of the organic solvent (g:mL) is 1:(8-10), such as 1:8, 1:9, 1:10, preferably 1:8; The ratio (g:mL) of the mass of baricitinib to the volume of purified water added for the first time is 1:(0.8-1.2), such as 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, and the ratio (g:mL) of the mass of baricitinib to the volume of purified water added for the second time is 1:(19-39), such as 1:19, 1:21, 1:24, 1:26, 1:28, 1:30, 1:32, 1:34, 1:36, 1:38, 1:39, preferably 1:39; The organic solvent is one or more of ethers, alcohols, amides and nitriles.

[0016] Furthermore, in the organic solvent, the ether is tetrahydrofuran, the alcohol is any one or more of n-butanol, ethanol, and methanol, the amide is DMF, the nitrile is acetonitrile, and the organic solvent is preferably tetrahydrofuran.

[0017] The present invention also provides a pharmaceutical composition, comprising the baricitinib X crystalline form and one or more pharmaceutically acceptable excipients; The excipients include fillers, disintegrants, and lubricants; The filler is selected from any one or more of pregelatinized starch, corn starch, lactose, mannitol, and microcrystalline cellulose; the disintegrant is selected from any one or more of cross-linked polyvinyl pyrrolidone, cross-linked povidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and microcrystalline cellulose; the lubricant is selected from any one or more of magnesium stearate, silicon dioxide, talc, magnesium lauryl sulfate, and sodium lauryl sulfate; The dosage form of the pharmaceutical composition is tablet.

[0018] Furthermore, the particle size D90 of the baricitinib X crystal form in the pharmaceutical composition is 30-40 μm.

[0019] The present invention also provides a method for preparing the pharmaceutical composition, which adopts a powder direct tableting process.

[0020] Furthermore, the powder direct tableting process comprises the following steps: S1: mixing baricitinib with an equal amount of a filler to obtain mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining filler and disintegrant to obtain mixed powder 2; S3: adding the lubricant to the mixed powder 2, continuing to mix, tableting, and film coating to obtain the pharmaceutical composition; The powder direct tableting method refers to a method in which the active ingredients of a drug are uniformly mixed with excipients and other components, and the mixed powder is directly made into tablets without granulation. Powder direct compression has the advantages of fewer preparation process steps, saving time and cost, etc. For the direct powder tableting process, the powder properties such as the fluidity, filling and compressibility of the material directly affect the mixing and transfer of the material in the production process, and affect the quality indicators such as the loading difference and content uniformity of the preparation. The physical and chemical properties of most drugs cannot meet the requirements of direct powder tableting, and there are defects such as large viscosity, poor fluidity or poor compressibility, which easily cause the hardness, loading difference, content uniformity, sticking and cracking of the final product. The baricitinib X crystal form prepared by the present invention has excellent powder properties, good particle size uniformity, small electrostatic effect, and is not easy to stick into agglomerates. As a raw material for the active ingredient of the preparation, it can be directly used for direct powder compression without being processed by pulverization, recrystallization, etc. to obtain better fluidity and compressibility.

[0021] In summary, compared with the prior art, the present invention achieves the following technical effects: (1) The particle size uniformity of the baricitinib X crystalline form provided by the present invention is good; (2) The baricitinib X crystal form provided by the present invention has excellent powder properties, and the powder fluidity and compressibility can meet the requirements of the rotary tablet press, and has good filling performance, and the corresponding pharmaceutical composition can be prepared by the powder direct compression process; (3) The baricitinib X crystal form provided by the present invention has good crystal stability under strong light, high temperature and high humidity conditions, and is convenient for storage, transportation and pharmaceutical preparation; (4) The baricitinib X crystal form provided by the present invention has a low powder elastic recovery rate, which can prevent the prepared pharmaceutical composition tablets from producing fragments or cracks; (5) The in vitro release rate of the pharmaceutical composition tablets prepared from the baricitinib X crystal form provided by the present invention is basically consistent with that of the marketed product, and can meet the application requirements. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0023] Figure 1 This is the XRPD pattern of the baricitinib Form X of Example 1 of the present invention; Figure 2 This is the DSC graph of the baricitinib X crystal form of Example 1 of the present invention; Figure 3 This is a release curve of baricitinib tablets in a comparative test between the self-developed formulation and the reference formulation in Example 12 of the present invention. DETAILED DESCRIPTION

[0024] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0025] Example The present invention is further described below in conjunction with specific examples and comparative examples. The following specific examples are all preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the following examples, and are particularly not limited to the types of the various component raw materials used in the following specific examples.

[0026] 1. The sources of raw materials for the embodiments and comparative examples are as follows: Unless otherwise specified, the raw materials used in the examples and comparative examples of the present invention are commercially available.

[0027] 2. Various performance test methods (1) Crystalline X-ray powder diffraction test: determined using the "Chinese Pharmacopoeia 2020 Edition, Part 4, General Chapter 0451 X-ray Diffraction Method 2".

[0028] (2) Particle size test of Baricitinib X crystal form: The particle size of the sample was measured by dry method using an OMEC laser particle size analyzer.

[0029] (3) Baricitinib X crystal repose angle test: The fixed cone bottom method is used, that is, a certain amount of the powder to be tested is taken, and the powder is made to flow out evenly through the funnel at a certain vibration frequency until the highest cone is obtained. The angle between the inclined surface of the cone and the plane is measured to obtain the repose angle. This is repeated three times and the average value is taken. The angle of repose is the most commonly used parameter to characterize the fluidity of powders. The angle of repose reflects the dynamic friction coefficient between powder particles. The larger the angle of repose, the greater the friction coefficient and the worse the fluidity of the powder. When the angle of repose is less than 30°, the fluidity of the powder is good. When the angle of repose is less than 40°, it can meet the fluidity requirements in the production process. When it is greater than 45°, the fluidity of the powder is poor.

[0030] (4) Baricitinib X crystal loose density test: Take a 50 mL measuring cylinder, add a certain volume of the powder to be tested at a uniform speed through a funnel, accurately weigh the powder, and record the powder volume. Repeat the measurement 6 times to calculate the loose density; The bulk density of powder is related to its filling property. If the bulk density of powder is large, it is conducive to tight filling. On the contrary, there will be a large number of voids in the powder with small bulk density. Usually, during production, the bulk density greater than 0.4 g / mL can meet better fluidity, while when it is less than 0.3 g / mL, there may be many voids in the powder.

[0031] (5) Tap density test of baricitinib X crystal form: The measuring cylinder containing the powder sample to be tested under the bulk density measurement item was allowed to fall freely from a height of 2 cm above the table. This was repeated 300 times and the volume after tapping was recorded. The tap density was calculated after 6 parallel measurements.

[0032] (6) Calculation of Hausner ratio of baricitinib Form X: The calculation formula is Hausner ratio = tap density / bulk density. When the Hausner ratio is greater than 1.5, the powder is viscous and has poor fluidity. When the Hausner ratio is less than 1.2, it indicates that the powder has good fluidity and filling properties.

[0033] (7) Calculation of Carr's index of baricitinib X crystal form: The calculation formula is Carr's index = (tapped density - bulk density) / tapped density; when the Carr's index is below 20%, the fluidity is good; when it is 23% to 28%, the powder fluidity is poor; when it is 40% to 50%, the powder is difficult to flow out of the container automatically; The Hausner ratio and Carr's index are indicators used to evaluate the fluidity of powders, and their magnitudes reflect the cohesion and softness of the powders.

[0034] (8) Stability test: The samples were placed under strong light, high temperature and high humidity conditions, and stability tests were conducted on the 0th, 10th and 30th days, respectively. The brightness range of the strong light environment was 5000±500 xl, the high temperature environment was 60°C, and the high humidity environment was 25°C / RH92.5%.

[0035] (9) Karnofsky index calculation: Karnofsky index = (1-loose density / tapped density)*100%; Determination of bulk density: vibrate the sample powder evenly in a 100 mL cup with a certain intensity, scrape off the excess powder on the cup with a scraper, weigh it, and divide the weight by 100 to get the bulk density (g / mL); Tapping density determination: While the powder flows evenly into a 100 mL cup, hit the cup with a certain intensity (60 times / minute), scrape off the excess powder on the cup with a scraper, weigh it, and divide the weight by 100 to get the tapping density (g / mL); The Carfella index reflects the compressibility and filling performance of the powder. Powders with a large Carfella index have good compressibility but poor fluidity. Powders with a small Carfella index have good filling and fluidity but poor compressibility. When the Carfella index is between 15% and 25%, the fluidity and compressibility of the powder can meet the requirements of the rotary tablet press.

[0036] (10) Determination by Chuanbei equation: Pour the powder into a 50 mL measuring cylinder at a constant speed and slowly using a funnel. Let the measuring cylinder containing the powder fall freely from a height of 1 cm above the horizontal tabletop onto the tabletop. Record the number of falls n and the corresponding volume Vn. Use the Chuanbei equation as follows for data processing: N / C=N / a+1 / ab In the formula, C is the relative volume reduction fraction of the powder, N is the number of tapping times, N / C is the ordinate, and N is the abscissa. The slope of the straight line is 1 / a, and the intercept is 1 / ab. The a and b values ​​reflect the fluidity and filling properties of the powder. The larger the a value, the better the compressibility, but the poorer the fluidity. Conversely, the worse the compressibility, the better the fluidity, the smaller the 1 / b value, and the better the filling property of the powder. The Chuanbei equation reflects the compressibility and filling property of the powder.

[0037] (11) Determination of powder elastic recovery rate: ER (%) = [(H t -H0) / H0]*100%, the powder was directly pressed into tablets under a certain pressure, and the tablet thickness H0 when pressed and the tablet thickness H0 after the pressure was released and placed for 24 hours were measured respectively. t ; Elastic recovery rate refers to the elastic expansion of the tablet due to internal stress after the tablet is removed from the die hole. If the tablet has a large elastic recovery rate after the pressure is released, it will cause greater damage to the tablet pressing equipment and is prone to cracking.

[0038] (12) Dissolution test method: The dissolution test was carried out according to the "General Rules 0931 Method 2 of Part 4 of the 2020 edition of the Chinese Pharmacopoeia"; The dissolution medium used was 900 mL of 50 mmol / L sodium acetate aqueous solution (the pH was adjusted to 4.5 using glacial acetic acid); the rotation speed was 75 r / min.

[0039] Example 1 Preparation method of baricitinib Form X (sample A): 2 g of baricitinib was transferred to a reactor, 16 mL of tetrahydrofuran was added, the system was heated to 60°C and stirred, 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 78 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample A, with a yield of about 95%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 1. Figure 1 This is the XRPD diagram of the baricitinib Form X in Example 1, Figure 2 This is the DSC graph of baricitinib Form X of Example 1.

[0040] Table 1

[0041] Example 2 Preparation method of baricitinib Form X (sample B): 2 g of baricitinib was transferred to a reactor, 16 mL of methanol was added, the system was heated to 60°C and stirred, 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 38 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample B, with a yield of about 91%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 2.

[0042] Table 2

[0043] Example 3 Preparation method of baricitinib Form X (sample C): 2 g of baricitinib was transferred to a reactor, 16 mL of ethanol was added, the system was heated to 60°C and stirred, 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 58 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample C, with a yield of about 91%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 3.

[0044] Table 3

[0045] Example 4 Preparation method of baricitinib Form X (Sample D): 2 g of baricitinib was transferred to a reactor, 16 mL of n-butanol was added, the system was heated to 60°C and stirred, 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 78 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample D, with a yield of about 90%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 4.

[0046] Table 4

[0047] Example 5 Preparation method of baricitinib Form X (Sample E): 2 g of baricitinib was transferred to a reactor, 18 mL of DMF was added, the system was heated to 60°C, stirred, 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 78 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample E, with a yield of about 89%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 5.

[0048] Table 5

[0049] Example 6 Preparation method of baricitinib Form X (Sample F): 2 g of baricitinib was transferred to a reactor, 20 mL of acetonitrile was added, the system was heated to 60°C, stirred, and then 2 mL of purified water was added to the system, the mixture was stirred for 1 hour, 78 mL of purified water was added, the mixture was stirred for 1 hour, the mixture was cooled to room temperature, aged, filtered, and dried to obtain an off-white solid, i.e., baricitinib X crystal form sample F, with a yield of about 92%; The X-ray powder diffraction data of the crystal form obtained in this example are shown in Table 6.

[0050] Table 6

[0051] Table 7

[0052] The baricitinib crystal form I used in the original marketed formulation product was used as the parallel control sample G, and the angle of repose, bulk density and tap density of samples AF and sample G of Examples 1-6 were measured respectively, and the Hausner ratio and Carr's index were calculated. The results are shown in Table 7. From the test data in Table 7, it can be seen that the baricitinib crystal form AF prepared by the present invention has good particle size uniformity, small electrostatic effect, and is not easy to adhere to agglomerate. 90The repose angle of baricitinib I crystal form sample G is greater than 40°, indicating that its fluidity can meet the production requirements. The repose angle of baricitinib I crystal form sample G is greater than 40°, indicating that its fluidity is poor. The bulk density of samples AF is greater than 0.4 g / mL, indicating that the filling performance is good and better than sample G. The corresponding Hausner ratio and Carr's index also show that the baricitinib X crystal form of the present invention has good fluidity and low viscosity. The results are consistent with the repose angle judgment. The Hausner ratio of sample G is 2.21, and the Carr's index is 54.7%. The volume after compaction is reduced by more than half, indicating that it has high viscosity and poor powder fluidity. It is judged that the baricitinib X crystal form of the present invention has excellent powder properties compared with the baricitinib I crystal form, and can be prepared by powder direct tableting method for pharmaceutical composition, which has the advantages of fewer preparation process steps, saving time and cost, etc.

[0053] Table 8

[0054] The stability of the baricitinib X crystal form sample A of Example 1 and the baricitinib I crystal form sample G used in the above-mentioned original research and marketed preparation product was investigated under strong light, high temperature and high humidity conditions, and the results are shown in Table 8. It can be seen from the test data in Table 8 that compared with the baricitinib I crystal form, the baricitinib X crystal form prepared by the present invention has good crystal stability and is convenient for storage, transportation and pharmaceutical preparation.

[0055] Example 7 The preparation of the X-crystalline baricitinib tablets includes using the X-crystalline baricitinib prepared in Example 1 as the raw material to prepare a pharmaceutical composition (baricitinib tablets), and its composition and proportion are as follows:

[0056] Baricitinib tablets are prepared by a powder direct compression process, comprising the following steps: S1: mixing the baricitinib X crystalline form with an equal amount of lactose to obtain a mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining lactose, microcrystalline cellulose and cross-linked polyvinyl pyrrolidone in a mixer to obtain mixed powder 2; S3: adding magnesium stearate to mixed powder 2, continuing to mix to obtain mixed powder 3, tableting, and film coating to obtain baricitinib tablets; The mixed powder 3 is sampled as mixed powder sample IR; The preparation method of Example 7 was adopted, except that the baricitinib X crystal form in the pharmaceutical composition prescription was replaced with the baricitinib I crystal form, and mixed powder 3 was prepared and sampled as mixed powder sample IT.

[0057] Example 8 The preparation of the X-crystalline baricitinib tablets includes using the X-crystalline baricitinib prepared in Example 1 as the raw material to prepare a pharmaceutical composition (baricitinib tablets), and its composition and proportion are as follows:

[0058] Baricitinib tablets are prepared by a powder direct compression process, comprising the following steps: S1: mixing the baricitinib X crystalline form with an equal amount of lactose to obtain a mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining lactose, microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, and low-substituted hydroxypropyl cellulose in a mixer to obtain mixed powder 2; S3: adding magnesium stearate and magnesium lauryl sulfate to mixed powder 2, continuing to mix to obtain mixed powder 3, tableting, and film coating to obtain baricitinib tablets; The mixed powder 3 is sampled as mixed powder sample II-R; The preparation method of Example 8 was adopted, only the baricitinib X crystal form in the pharmaceutical composition prescription was replaced with the baricitinib I crystal form, and mixed powder 3 was prepared and sampled as mixed powder sample II-T.

[0059] Example 9 The preparation of the X-crystalline baricitinib tablets includes using the X-crystalline baricitinib prepared in Example 1 as the raw material to prepare a pharmaceutical composition (baricitinib tablets), and its composition and proportion are as follows:

[0060] Baricitinib tablets are prepared by a powder direct compression process, comprising the following steps: S1: mixing the baricitinib X crystalline form with an equal amount of lactose to obtain a mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining lactose, cross-linked polyvinyl pyrrolidone and low-substituted hydroxypropyl cellulose in a mixer to obtain mixed powder 2; S3: adding magnesium stearate and talc to mixed powder 2, continuing to mix to obtain mixed powder 3, tableting, and film coating to obtain baricitinib tablets; The mixed powder 3 is sampled as mixed powder sample III-R; The preparation method of Example 9 was adopted, except that the baricitinib X crystal form in the pharmaceutical composition prescription was replaced with the baricitinib I crystal form, and mixed powder 3 was prepared and sampled as mixed powder sample III-T.

[0061] Example 10 The preparation of the X-crystalline baricitinib tablets includes using the X-crystalline baricitinib prepared in Example 1 as the raw material to prepare a pharmaceutical composition (baricitinib tablets), and its composition and proportion are as follows:

[0062] Baricitinib tablets are prepared by a powder direct compression process, comprising the following steps: S1: mixing the baricitinib X crystal form with an equal amount of mannitol to obtain mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining mannitol, pregelatinized starch and cross-linked polyvinylpyrrolidone in a mixer to obtain mixed powder 2; S3: adding magnesium stearate and silicon dioxide to mixed powder 2, continuing to mix to obtain mixed powder 3, tableting, and film coating to obtain baricitinib tablets; The mixed powder 3 is sampled as mixed powder sample IV-R; The preparation method of Example 10 was adopted, only the baricitinib X crystal form in the pharmaceutical composition prescription was replaced with the baricitinib I crystal form, and mixed powder 3 was prepared and sampled as mixed powder sample IV-T.

[0063] Embodiment 11 The preparation of the X-crystalline baricitinib tablets includes using the X-crystalline baricitinib prepared in Example 1 as the raw material to prepare a pharmaceutical composition (baricitinib tablets), and its composition and proportion are as follows:

[0064] Baricitinib tablets are prepared by a powder direct compression process, comprising the following steps: S1: mixing the baricitinib X crystalline form with an equal amount of lactose in an equal-incremental manner to obtain a mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining lactose, corn starch, mannitol, and cross-linked sodium carboxymethyl cellulose in a mixer to obtain mixed powder 2; S3: adding magnesium stearate and sodium lauryl sulfate to mixed powder 2, continuing to mix to obtain mixed powder 3, tableting, and film coating to obtain baricitinib tablets; The mixed powder 3 is sampled as a mixed powder sample VR; The preparation method of Example 11 was adopted, only the baricitinib X crystal form in the pharmaceutical composition prescription was replaced with the baricitinib I crystal form, and mixed powder 3 was prepared and sampled as mixed powder sample VT.

[0065] The mixed powder samples IR~VR and IT~VT prepared in Examples 7-11 were tested for fluidity and compressibility to determine and compare the powder properties of the raw material and auxiliary material mixed powders before direct tableting. The test data are shown in Table 9, where the fluidity is characterized by the angle of repose parameter: Table 9

[0066] The test results show that in Examples 7-11, after the X-crystal baricitinib is mixed with the corresponding excipients, the angle of repose is less than 40°, and the fluidity can meet the production requirements; and the Karl-Frank index is between 15%-25%, and the fluidity and compressibility of the powder can meet the requirements of the tablet press; the fluidity trend reflected by the a value in the Chuanbei equation is consistent with the angle of repose and the Karl-Frank index, and has good filling performance, so the X-crystal baricitinib prepared by the present invention has excellent powder properties, is suitable for the direct powder compression process, and can achieve the advantages of fewer process steps, saving time and cost in the preparation of the pharmaceutical composition. However, after the corresponding I-crystal baricitinib is mixed with the corresponding excipients, there is still a problem of poor fluidity, the filling performance is not as good as the X-crystal mixed powder, and the powder elastic recovery rate is high, and the prepared tablets are more likely to produce fragments or cracks.

[0067] Based on the data in Tables 7-9 for testing the powder properties, particle size uniformity, and crystal stability of different crystal forms of baricitinib and mixed powders of different crystal forms of baricitinib and corresponding excipients, the baricitinib X crystal form prepared by the present invention has obvious advantages over the baricitinib I crystal form used in the original research and marketed formulation products.

[0068] Example 12 The baricitinib tablets (self-made preparation) prepared in Example 7 were compared with the original product Alamine that has been marketed. ® (reference preparation) for in vitro dissolution comparison study. In vitro dissolution test is often used to guide the development of drug preparations, evaluate the consistency of quality within and between batches of preparations, and evaluate the consistency of quality and efficacy before and after changes in drug prescription process. The test results are shown in Table 10: Table 10

[0069] The above data show that the in vitro release of the baricitinib X crystal form prepared by the present invention is basically consistent with that of the marketed product after direct tableting of the powder, and the cumulative release in 20 minutes can reach more than 80%. It can be seen that the baricitinib X crystal form of the present invention can effectively meet the standard requirements of customers and the market when applied to pharmaceutical compositions, and because the raw material baricitinib X crystal form has excellent powder characteristics and stable physicochemical properties, the process for preparing the pharmaceutical composition is simple, and it is also conducive to continuous industrial production.

[0070] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A baricitinib X crystal form, It is characterized in that Its X-ray powder diffraction pattern has characteristic peaks at 2theta values ​​of 4.26°±0.2°, 12.58°±0.2°, 16.39°±0.2°, 16.77°±0.2°, 19.17°±0.2°, 19.34°±0.2°, 25.21°±0.2°, 25.44°±0.2°, and 29.48°±0.2°.

2. The baricitinib X crystal form according to claim 1, It is characterized in that Its X-ray powder diffraction pattern has characteristic peaks at one or more of the 2theta values ​​of 25.63°±0.2°, 29.93°±0.2°, 33.29°±0.2°, 37.24°±0.2°, and 38.14°±0.2°.

3. The baricitinib X crystal form according to claim 2, It is characterized in that Its X-ray powder diffraction pattern has characteristic peaks at 2theta values ​​of 25.63°±0.2°, 29.93°±0.2°, 33.29°±0.2°, 37.24°±0.2°, and 38.14°±0.2°.

4. The baricitinib X crystal form according to claim 1, It is characterized in that Its X-ray powder diffraction pattern is consistent with that in FIG1 .

5. The baricitinib X crystal form according to claim 1, It is characterized in that It has an endothermic peak at 215±2°C in DSC analysis.

6. A method for preparing the baricitinib X crystal form according to any one of claims 1 to 5, It is characterized in that The steps include: Add baricitinib to an organic solvent system, heat up and stir, add a small amount of purified water and then keep warm and stir, continue to add a large amount of purified water for crystallization, keep warm and stir again, then cool down, age, filter and dry to obtain baricitinib Form X; The ratio of the mass of baricitinib to the volume of the organic solvent is 1:(8-10); The ratio of the mass of the baricitinib to the volume of the purified water added for the first time is 1:(0.8-1.2), and the ratio of the mass of the baricitinib to the volume of the purified water added for the second time is 1:(19-39); The organic solvent is one or more of ethers, alcohols, amides and nitriles.

7. The preparation method according to claim 6, It is characterized in that In the organic solvent, the ether is tetrahydrofuran, the alcohol is any one or more of n-butanol, ethanol and methanol, the amide is DMF, and the nitrile is acetonitrile.

8. A pharmaceutical composition, It is characterized in that Comprising the baricitinib X crystalline form according to any one of claims 1 to 5 and one or more pharmaceutically acceptable excipients; The excipients include fillers, disintegrants and lubricants; The filler is selected from any one or more of pregelatinized starch, corn starch, lactose, mannitol, and microcrystalline cellulose; the disintegrant is selected from any one or more of cross-linked polyvinyl pyrrolidone, cross-linked povidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and microcrystalline cellulose; the lubricant is selected from any one or more of magnesium stearate, silicon dioxide, talc, magnesium lauryl sulfate, and sodium lauryl sulfate.

9. A method for preparing the pharmaceutical composition according to claim 8, It is characterized in that The product is prepared by direct powder compression process.

10. The preparation method according to claim 9, It is characterized in that The powder direct tableting process comprises the following steps: S1: mixing baricitinib with an equal amount of a filler to obtain mixed powder 1; S2: fully mixing the mixed powder 1 with the remaining filler and disintegrant to obtain mixed powder 2; S3: adding the lubricant to the mixed powder 2, continuing to mix, tableting, and film coating to obtain the pharmaceutical composition.

Citation Information

Patent Citations

  • Crystal form of JAK inhibitor and preparation method thereof

    CN105924444A

  • Method for preparing spherical baricitinib crystal

    CN109384792A

  • Crystalline form of baricitinib

    IN201617038592A

  • Crystalline form of baricitinib and method for preparation thereof

    TW202117102A

  • Crystalline form of baricitinib

    US20170204097A1